fda 503b exemption
Why 3 Health Plans Fail Post Semaglutide Exclusion
Three health plans have already missed up to 30% of projected savings after the FDA’s 503B proposal removed key GLP-1 drugs from bulk compounding. The rule forces insurers to shift from low-cost bulk purchases to higher-price point-to-point contracts, straining budgets and disrupting patient access. Medical Disclaimer: This article is